EUCTR2010-018334-51-DE进行中（未招募）不适用
An open-label, non-controlled study to immunize healthy volunteers actively working with or in the vicinity of replicating Vaccinia virus with IMVAMUNE® (MVA-BN®)
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Healthy male and female subjects who will work with or in the vicinity of replicating Vaccinia virus and are at-risk for contracting vaccinia infection during work and who volunteer for the program.
- •2.Health status will be assessed by medical history, physical examination and clinical laboratory tests.
- •3.Age: 18 to 60 (inclusive) years
- •4.Women of child-bearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to each vaccination.
- •5.Women of child-bearing potential must agree to use an acceptable method of contraception during the vaccination period, and must continue to use it for at least 28 days after the last vaccination.
- •6.Read, signed and dated informed consent form (ICF) after being advised of the risks and benefits of the trial in a language understood by the subject prior to performance of any trial specific procedure.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Pregnant or breast-feeding women.
- •2.History of any serious medical condition, which in the opinion of the investigator would compromise the safety of the subject.
- •3.Present uncontrolled serious infection i.e., not responding to antimicrobial therapy.
- •4.History of or active autoimmune disease.
- •5.Known or by the clinical investigator suspected relevant impairment of immunologic function including, but not limited to, clinically significant liver disease; uncontrolled diabetes mellitus; moderate to severe kidney impairment or post organ transplant subjects which might interfere with the safety and/or immunogenicity of IMVAMUNE® vaccination.
- •6.History of malignancy, other than squamous cell or basal cell skin cancer, unless there has been surgical excision that is considered to have achieved cure.
- •7.History of coronary heart disease, myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke or transient ischemic attack, uncontrolled high blood pressure, or any other clinical relevant heart condition to the discretion of the investigator.
- •8.History of allergies or reactions to eggs, egg products, or gentamycin.
- •9.History of any anaphylactic shock or severe allergic reaction requiring immediate treatment.
- •10.Having received any vaccinations or planned vaccinations with a live vaccine within 28 days or a killed vaccine within 14 days prior to or after IMVAMUNE® vaccination.
- •11.Chronic administration (defined as more than 6 days) of systemic corticosteroids within 90 days of the first planned vaccination.
- •12.Use of any investigational or non-registered drug or vaccine within 30 days preceding the first IMVAMUNE® vaccine dose, or planned administration of such a drug during the trial period.
研究者
相似试验
进行中（未招募）
不适用
An open label, Phase II study of vaccination with Survivin peptides emulsified in Montanide ISA 51VG after IMP 321 injection in prostate carcinoma patients with biochemical failure (PROVAX study) - NDProstate cancer, biochemical failure after all potentially curative standard local therapies (radiotherapy, brachytherapy and surgery) or biochemical progression while patients have castrated levels of testosterone or after first-line anti hormonal therapyMedDRA version: 12.1Level: LLTClassification code 10001200Term: Adenocarcinoma of the prostate stage IEUCTR2009-017798-39-ITISTITUTO NAZIONALE PER LA CURA TUMORI
进行中（未招募）
不适用
Safety and reactogenicity of GSK Biologicals’ DTPa-IPV/Hib (Infanrix-IPV/Hib) in infants.Healthy volunteers (Primary immunisation of healthy infants in the first year of life against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b diseases).EUCTR2015-001513-27-Outside-EU/EEAGlaxoSmithKline Biologicals50
进行中（未招募）
不适用
Randomized, open phase II study of immunization with the recombinant MAGE-3 protein combined with adjuvant AS02B or AS15 in patients with unresectable and progressive metastatic cutaneous melanoma.nresectable and progressive metastatic cutaneous melanomaMedDRA version: 9.1Level: LLTClassification code 10027480Term: Metastatic malignant melanomaEUCTR2004-001937-40-ITE.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER68
进行中（未招募）
1 期
Randomized, open phase II study of immunization with the recombinant MAGE-3 protein combined with adjuvant AS02B or AS15 in patients with unresectable and progressive metastatic cutaneous melanomanresectable and progressive metastatic cutaneous melanomaMedDRA version: 7.0Level: LLTClassification code 10027155EUCTR2004-001937-40-ESEuropean Organisation for Research and Treatment of Cancer
进行中（未招募）
1 期
A clinical study on safety, immune activation and the effect of treatment with histamine and IL- 2 in adult tyrosine kinase inhibitor-treated patients with chronic myeloid leukemia (CML )Chronic Myeloid Leukemia (CML)EUCTR2016-002728-94-SESahlgrenska University Hospital15